Market Capitalization

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

The Chinese auto-tech firm regained Nasdaq's minimum bid price but still faces delisting over its low market value, setting up a critical hearing.

Biotech firm Bright Minds Biosciences closes a massive $175M deal, fueling its race to develop novel drugs for epilepsy and rare neurological conditions.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

ChipMOS reports stunning 20.8% Q4 growth, highlighting a memory chip frenzy fueled by AI and datacenters. Is this the start of a new tech supercycle?

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

With its radical solar car on the line, Aptera appoints a VW and BMW veteran as Chairman. Can traditional auto expertise finally launch a new era of efficiency?

With its Q4 earnings approaching, all eyes are on Federal Realty to see if its premium retail strategy can sustain its record dividend amid market shifts.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

Pan Global Resources has defined a major copper and gold resource in Spain, fueling the green energy transition and reviving a historic mining district.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

Rebranded and recapitalized, Future Mineral Resources is raising $4.5M to advance its gold, uranium, and nickel projects across three continents.

The shipping giant cashes in on eight older vessels, using a massive profit to slash debt, reward shareholders, and accelerate its sustainable fleet strategy.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.

Facing declining revenue but armed with a strong AI vision, Unisys CEO Mike Thomson prepares to address investors at the critical Needham Growth Conference.

Amid rising geopolitical risks, Taiwan's J-Star is exiting China to build an automated factory in the US, a bold move for the micro-cap company.

HighVista Strategies promotes three private equity experts to Partner, signaling a strategic reinforcement of its successful lower middle-market strategy.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.